Annovis Bio (NYSE:ANVS) Price Target Lowered to $12.00 at HC Wainwright

Annovis Bio (NYSE:ANVS) had its price objective dropped by research analysts at HC Wainwright from $30.00 to $12.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 315.08% from the company’s current price. HC Wainwright also issued estimates for Annovis Bio’s Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.66) EPS.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group decreased their target price on shares of Annovis Bio from $26.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. D. Boral Capital reissued a “hold” rating on shares of Annovis Bio in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $30.25.

Annovis Bio Trading Down 5.5%

ANVS stock opened at $2.89 on Monday. Annovis Bio has a 12-month low of $1.11 and a 12-month high of $17.88. The stock has a market cap of $56.33 million, a price-to-earnings ratio of -0.65 and a beta of 1.62. The business’s 50-day moving average is $1.80 and its 200 day moving average is $3.11.

Annovis Bio (NYSE:ANVS) last released its earnings results on Tuesday, May 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15. As a group, equities analysts forecast that Annovis Bio will post -2.19 EPS for the current fiscal year.

Institutional Trading of Annovis Bio

Several institutional investors have recently made changes to their positions in ANVS. Cubist Systematic Strategies LLC purchased a new stake in shares of Annovis Bio during the 4th quarter valued at approximately $258,000. Warberg Asset Management LLC purchased a new stake in shares of Annovis Bio during the 1st quarter valued at approximately $58,000. Jane Street Group LLC raised its position in shares of Annovis Bio by 99.7% during the 4th quarter. Jane Street Group LLC now owns 68,107 shares of the company’s stock valued at $343,000 after buying an additional 34,001 shares during the period. Greenwich Wealth Management LLC raised its position in shares of Annovis Bio by 93.9% during the 4th quarter. Greenwich Wealth Management LLC now owns 31,951 shares of the company’s stock valued at $161,000 after buying an additional 15,476 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Annovis Bio during the 4th quarter valued at approximately $65,000. Hedge funds and other institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.